Biocure Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - March 25, 2022) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) ("Biocure" or the "Company")...
Day: March 25, 2022
Advent Galaxy(TM), Division of TGI and AllStarHealth Brands Retain GIANT.NET to Explore Creation of its Own Crypto and Development of NFTs
MIAMI, FL / ACCESSWIRE / March 25, 2022 / TGI SOLAR POWER GROUP INC. ("TGI"), a diversified technology and environmentally...
Franchise Global Health Inc. Announces Completion Of Qualifying Transaction
NOT FOR DISSEMINATION IN THE U.S. OR THROUGH U.S. NEWSWIRESTORONTO, ON and VANCOUVER, BC / ACCESSWIRE / March 25, 2022...
Dr. June Gower Explains What It Took to Become a Field Medic in the Air Force and U.S. Army
Former field medic Dr. June Gower explains what it takes to fulfill this role in the armed forces.HOOD RIVER, OR...
Aquarius Surgical Technologies Announces Share Issuance
TORONTO, ON / ACCESSWIRE / March 25, 2022 / Aquarius Surgical Technologies Inc. (CSE:ASTI) announces that it has issued 100,000...
Xcelerate, Inc. Files Medical Surgical Device Patent
MAULDIN, SC / ACCESSWIRE / March 25, 2022 / Xcelerate, Inc. (OTC Markets:XCRT) recently announced that it signed a Membership...
NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference
ZURICH, SWITZERLAND / ACCESSWIRE / March 25, 2022 - NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss...
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage Corp I
PALO ALTO, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc....
INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022
International Conference on Alzheimer's and Parkinson's Diseases Provides New Insights into the Role of Neuroinflammation in AD and the Promise...
CHMP recommends EU approval of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large...
POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update
Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of SPLASH trial ongoing, top line...
Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease
CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared...
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment...
Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting
Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with...
Noema Pharma to Attend and Present at Stifel 2022 CNS Days
BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical-stage company targeting orphan and large-market central nervous...
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2
- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known...
Morphic Therapeutic Announces Initiation of EMERALD-1 Phase 2a Clinical Trial of MORF-057 in Patients with Ulcerative Colitis
MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases Phase 2b EMERALD-2 clinical trial of...
ORYZON to Give Updates on Corporate Progress in March and April
Virtual Bio-Europe Spring 2022Kempen Life Sciences Conference Asebio Investor DayMADRID, Spain and CAMBRIDGE, Mass., March 25, 2022 (GLOBE NEWSWIRE) --...
Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting
Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001 regardless of subtype BASKING RIDGE,...
Angle PLC Announces Identifying Therapeutic Targets in TNBC Patients
PARSORTIX SHOWS POTENTIAL FOR IDENTIFYING THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCERParsortix system harvests intact CTCs for whole...